Eye scan may detect Alzheimer's disease early

Image
Press Trust of India Toronto
Last Updated : Jul 28 2016 | 12:13 PM IST
Scientists have developed a new non-invasive eye scan that can identify Alzheimer's long before the onset of symptoms, an advance that may help develop preventative strategies for the neurodegenerative disease.
The test uses polarised light to highlight deposits called amyloid proteins found at the back of patients' retinas decades before they experience cognitive decline.
"The ability to detect amyloid deposits in the retina prior to disease symptoms may be an essential tool for the development of preventative strategies for Alzheimer's and other dementias," said Melanie Campbell, professor at University of Waterloo in Canada.
In order to diagnose Alzheimer's disease and other forms of dementia, doctors currently rely on either a combination of late-stage symptoms and expensive positron emission tomography (PET) brain scans or tests on the brain after death.
The new method would give a less expensive, more available alternative to PET.
The research established the diagnostic method's proof of concept in both human and an animal model.
Campbell showed that polarised light scans are as sensitive as other more established methods and can be done cost-effectively without using irritating dyes, making it potentially useful as an in-office screening tool.
"Amyloid proteins are made up of protein fibres with different refractive indices along and across the fibres," said Campbell.
"They light up the same way as when scotch tape is placed between two polarising filters. While other researchers thought that a dye was needed to make the protein visible, we were able to achieve the same results using optics and additional computer processing," she said.
Amyloid beta protein deposits in the brain have been proven to be present in patients decades before they experience symptoms of the disease.
Although the reasons this protein appears are still being debated, the fact that it also deposits in the retina, an extension of the brain, means these deposits can be used as a biomarker for diagnosing Alzheimer's disease long before symptoms appear.
"Early diagnosis is important, especially since treatment options are more limited later in the disease," said Campbell.
"Widely available, inexpensive, early detection of amyloid would help researchers develop more effective treatments before the onset of symptoms," she said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 28 2016 | 12:13 PM IST

Next Story